160 related articles for article (PubMed ID: 18942400)
21. Androgen deprivation therapy for prostate cancer.
Bahnson R
J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
[No Abstract] [Full Text] [Related]
22. Duration of testosterone suppression and the risk of death from prostate cancer in men treated with radiation and 6 months of hormone therapy.
Palma D; Pickles T
Cancer; 2008 May; 112(10):2322-3; author reply 2323. PubMed ID: 18327816
[No Abstract] [Full Text] [Related]
23. A nonlinear model with competition between prostate tumor cells and its application to intermittent androgen suppression therapy of prostate cancer.
Shimada T; Aihara K
Math Biosci; 2008; 214(1-2):134-9. PubMed ID: 18420226
[TBL] [Abstract][Full Text] [Related]
24. Novel secondary hormonal therapy in advanced prostate cancer: an update.
Van Allen EM; Ryan CJ
Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958
[TBL] [Abstract][Full Text] [Related]
25. Absence of relationship between steroid hormone levels and prostate cancer tumor grade.
Sher DJ; Mantzoros C; Jacobus S; Regan MM; Lee GS; Oh WK
Urology; 2009 Feb; 73(2):356-61; discussion 361-2. PubMed ID: 19036418
[TBL] [Abstract][Full Text] [Related]
26. What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?
Kollmeier MA; Zelefsky MJ
Nat Clin Pract Urol; 2008 Nov; 5(11):584-5. PubMed ID: 18813218
[TBL] [Abstract][Full Text] [Related]
27. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
[TBL] [Abstract][Full Text] [Related]
28. Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice.
Sayyid RK; Sayyid AK; Klaassen Z; Fadaak K; Goldberg H; Chandrasekar T; Ahmad A; Leao R; Perlis N; Chadwick K; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta AR; Fleshner NE
J Urol; 2018 Jan; 199(1):251-256. PubMed ID: 28751266
[TBL] [Abstract][Full Text] [Related]
29. [Principles for the conservative drug therapy treatment of prostate cancer].
Hofmann W
Z Urol Nephrol; 1981 Sep; 74(9):697-704. PubMed ID: 7314992
[No Abstract] [Full Text] [Related]
30. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer.
Gleave M; Klotz L; Taneja SS
Urol Oncol; 2009; 27(1):81-6. PubMed ID: 19111804
[TBL] [Abstract][Full Text] [Related]
31. [Prolactin and cancer of the prostate (III). Changes in plasma prolactin and testosterone after hormone treatment in prostatic cancer].
Maganto Pavón E; Mateos Torres JA; Mayayo Dehesa T; Allona Almagro A; Boronat Tormo F; Escudero Barrilero A
Arch Esp Urol; 1982; 35(4):222-33. PubMed ID: 7138091
[No Abstract] [Full Text] [Related]
32. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur urol 2006;49:54-8.
Sharma R; Sundar S
Eur Urol; 2007 Apr; 51(4):1146. PubMed ID: 17161523
[No Abstract] [Full Text] [Related]
33. [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].
Pfitzenmaier J; Altwein JE
Aktuelle Urol; 2009 Mar; 40(2):100-8. PubMed ID: 19253209
[TBL] [Abstract][Full Text] [Related]
34. [Role of hormonotherapy in the treatment of metastatic prostate cancer].
Lebret T; Méjean A
Prog Urol; 2008 Nov; 18 Suppl 7():S332-7. PubMed ID: 19070812
[TBL] [Abstract][Full Text] [Related]
35. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
[TBL] [Abstract][Full Text] [Related]
36. Radiotherapy for patients with localized hormone-refractory prostate cancer: results of the Patterns of Care Study in Japan.
Sasaki T; Nakamura K; Ogawa K; Onishi H; Okamoto A; Koizumi M; Shioyama Y; Mitsumori M; Teshima T;
BJU Int; 2009 Nov; 104(10):1462-6. PubMed ID: 19522869
[TBL] [Abstract][Full Text] [Related]
37. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
[TBL] [Abstract][Full Text] [Related]
38. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
Vis AN; Schröder FH
BJU Int; 2009 Nov; 104(9):1191-7. PubMed ID: 19624596
[TBL] [Abstract][Full Text] [Related]
39. Global update on the use of hormonal therapy for the management of high-risk prostate cancer: introduction.
Gomella LG
BJU Int; 2007 Jan; 99 Suppl 1():1. PubMed ID: 17229158
[No Abstract] [Full Text] [Related]
40. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials.
Bria E; Cuppone F; Giannarelli D; Milella M; Ruggeri EM; Sperduti I; Pinnarò P; Terzoli E; Cognetti F; Carlini P
Cancer; 2009 Aug; 115(15):3446-56. PubMed ID: 19484790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
